Effectiveness of Enhanced Recovery After Surgery Protocols for Robot Assisted Radical Prostatectomy: A Systematic Review and Meta-Analysis.

J Laparoendosc Adv Surg Tech AJul 8, 2026 (epub)
Clinical ResearchUrologyGeneral Surgery

Joshua Bruinsma, Nicholas A Clausen, Rostyslav Nikolenko et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of Enhanced Recovery After Surgery (ERAS) protocols in patients undergoing robotic-assisted radical prostatectomy (RARP). Involving 1314 patients, the study found that ERAS protocols significantly reduced length of stay (5.98 vs 7.45 days, Hedges' g -0.68) and improved gastrointestinal recovery without affecting complication rates or operative time.

Key findings

  • ERAS protocols reduced length of stay to 5.98 days compared to 7.45 days for standard care.
  • Time to flatus was shorter with ERAS at 1.66 days versus 2.03 days.
  • Time to defecation improved with ERAS, averaging 2.68 days compared to 3.13 days.
  • No significant differences were found in complication rates, operative time, or blood loss.

Why it matters

The findings suggest that ERAS protocols can enhance postoperative recovery in RARP patients, particularly in gastrointestinal function, which may lead to improved patient satisfaction and resource utilization in surgical settings.

Source

PubMed · PMID 42421337

Published in J Laparoendosc Adv Surg Tech A. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.